Search results for "Highlights"
SGLT2 inhibitors, GLP-1 receptor agonists compared for CV, renal outcomes
Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with fewer hospitalizations for heart failure and slower progression of kidney disease while glucagon-like peptide-1 (GLP-1) receptor agonists were associated with lower risk of stroke.
https://diabetes.acponline.org/archives/2019/03/08/3.htm
8 Mar 2019
Cardiovascular event rates similar among newer second-line medications for type 2 diabetes
The comparison of dipeptidyl peptidase-4 inhibitors with other drug classes did find higher rates of major adverse cardiovascular events with basal insulin, sulfonylureas, and meglitinides than with the newer drugs.
https://diabetes.acponline.org/archives/2019/01/11/2.htm
11 Jan 2019
AHA issues statement on coronary artery disease management in patients with diabetes
The American Heart Association (AHA) addressed use of antithrombotics, hypertension drugs, and cholesterol therapies in patients with stable coronary artery disease and diabetes, among other recommendations.
https://diabetes.acponline.org/archives/2020/05/08/1.htm
8 May 2020
Poor glycemic control associated with fracture in type 1 but not type 2 diabetes
Patients with type 1 diabetes and a mean three-year HbA1c level greater than 8.0% had a higher fracture risk than those with a mean three-year HbA1c level of 7.0% or less.
https://diabetes.acponline.org/archives/2019/02/08/3.htm
8 Feb 2019
Glycemic control worse over time in type 2 patients who decline insulin, study finds
In adults with uncontrolled type 2 diabetes who initially declined insulin versus those who initially accepted, median time to an HbA1c level below 7.0% was 50 months versus 38 months.
https://diabetes.acponline.org/archives/2020/03/13/1.htm
13 Mar 2020
Spotlight on depression in diabetes
Recent studies analyzed depression in diabetes, including associated causes of death, the potential benefits of peer support and a plant-based diet, and strategies for screening and treatment.
https://diabetes.acponline.org/archives/2018/11/09/5.htm
9 Nov 2018
Sulfonylureas not supported as second-line treatment for type 2 diabetes
Risk for major adverse cardiovascular events and all-cause mortality was higher when a sulfonylurea was added to metformin compared to other typical second- or third-line therapy options in a recent Danish study.
https://diabetes.acponline.org/archives/2020/04/10/1.htm
10 Apr 2020
SGLT2 inhibitors associated with increased risk of amputations, diabetic ketoacidosis
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists had similar rates of other adverse events, including bone fracture, acute kidney injury, serious urinary tract infection, venous thromboembolism, and acute pancreatitis.
https://diabetes.acponline.org/archives/2018/12/14/3.htm
14 Dec 2018
3 actions may help reluctant patients begin insulin therapy for type 2 diabetes
Patients' perceived helpfulness of certain actions by health care professionals was linked to earlier insulin initiation and greater insulin continuation over time, a survey found.
https://diabetes.acponline.org/archives/2019/02/08/2.htm
8 Feb 2019
DPP-4 inhibitors may be effective for some cases of inpatient hyperglycemia
A narrative review considered the available evidence on use of metformin, thiazolidinediones, sulfonylureas, sodium-glucose cotransporter-2 inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors in the hospital.
https://diabetes.acponline.org/archives/2020/06/12/1.htm
12 Jun 2020